Center for Inherited Blood Disorders

Running trials

• Recruiting

  A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

  NCT07226206· Phase 1/2· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

  NCT07416604· Phase 3· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

  NCT07285460· Phase 3· Source

• Recruiting

  Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

  NCT07080905· Phase 3· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

  NCT06439082· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A

  NCT05911763· Source

• Active, not recruiting

  Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors

  NCT04082429· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Haemophilia4 recruiting
• Sickle cell disease1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD

  NCT04930445· Source

Trial sites

• Center for Inherited Blood Disorders5 trials
• Ctr for Inherited Blood Disorders1 trial
• The Center for Inherited Blood Disorders- Site Number : 84000011 trial
• The Center for Inherited Blood Disorders- Site Number : 84000091 trial